Season's Savings | ₹5/mo for 3 months

₹199/month after first 3 months. Renews automatically. Terms apply.
10: Peptalk Deep Dive - TB-500 cover art

10: Peptalk Deep Dive - TB-500

10: Peptalk Deep Dive - TB-500

Listen for free

View show details
About this listen

This week: TB-500, the systemic half of the Wolverine stack — a synthetic fragment of thymosin beta-4, a 43-amino-acid protein found in almost every cell in the human body.

Jake and Cynthia unpack the mechanism (G-actin binding, cell migration, angiogenesis, the ILK-Akt survival pathway, anti-inflammatory signaling), the animal research on tendons, ligaments, heart and lung repair, the real evidence gap (encouraging reports, yet to be proven in human trials), the July 2026 FDA advisory vote, and why it's banned in sport. Plus a refreshed GLP pulse: the October 23 Pharmafile report on the indirect comparison of Lilly's oral Foundayo (orforglipron) against oral semaglutide; the latest oral GLP-1 prescription tracker; and Novo's new CagriSema analyses in women from the REDEFINE 1 trial.

For research and informational purposes only — not medical advice. Nothing on this show is a recommendation for any product or treatment.

Sources:

- Pharmafile (Oct 23, 2026) — Orforglipron shows weight and glucose advantages over oral semaglutide in indirect comparison (ACHIEVE-3 vs PIONEER-PLUS, 52 weeks; 1.46 points greater weight reduction, 0.31 points greater HbA1c reduction; indirect comparison, not head-to-head): https://pharmafile.com/news/orforglipron-shows-weight-and-glucose-advantages-over-oral-semaglutide-in-indirect-comparison/

- Fierce Pharma (updated Oct 23, 2026) — The Oral GLP-1 Tracker: Novo's Wegovy pill vs Lilly's Foundayo (Wegovy pill ~173K prescriptions, Foundayo ~58K, down ~4% week over week; Novo ~75% of oral pill market, Lilly over 25%): https://www.fiercepharma.com/pharma/oral-glp-1-tracker-launch-trajectories-lilly-foundayo-novo-wegovy-pill

- Reuters (Oct 20, 2026) — Novo's CagriSema helped women lose 25% of weight on average, analysis shows (REDEFINE 1: 25.0% mean weight loss at 68 weeks in 2,309 women vs 3.0% placebo; 26.7% / 24.8% / 23.1% across menopause stages; post hoc analyses, hypothesis-generating): https://dukecountry.fm/2026/10/20/novos-cagrisema-helped-women-lose-25-of-weight-on-average-analysis-shows/

- HealingMaps — TB-500 (thymosin beta-4 fragment) explainer: mechanism, WADA status, PCAC review: https://healingmaps.com/tb-500-thymosin-beta-4-fragment-wound-healing-peptide/

- PrimeLab Peptides — TB-500 tendon and ligament repair evidence (2026 rat Achilles study; 2013 rat MCL model): https://primelabpeptides.com/blogs/news/what-evidence-shows-tb-500-effectiveness-in-tendon-and-ligament-repair-post-injury

- PrimeLab Peptides — TB-500 and fibrosis/scar tissue (cardiac, lung fibrosis models): https://primelabpeptides.com/blogs/news/what-evidence-supports-tb-500-use-in-pulmonary-fibrosis-research

- Paragon Sports Medicine — TB-500 regulatory position, WADA S2 prohibition, 503A status: https://www.paragonsportsmedicine.com/peptides/tb-500

- TarzanOptimized — What is TB-500 (thymosin beta-4 fragment, systemic vs local repair): https://tarzanoptimized.com/blog/what-is-tb-500

- Frier Levitt — July 23–24, 2026 PCAC votes: six of seven peptides recommended for 503A Bulks List (TB-500 8–6): https://www.frierlevitt.com/news/fda-pcac-peptides-503a-compounding/

- Flow Wellness — July 2026 PCAC update: what the vote means and does not mean: https://flowwellness.com/new-peptides-may-be-available-soon/

- Impact Health Clinics — BPC-157/TB-500 FDA status: the July 2026 review, votes by substance: https://www.impacthealthclinics.com/blog/bpc-157-fda-status-2026

- Business Wire — Enhanced: PCAC vote context, Wolverine Stack (BPC-157 + TB-500) protocol: https://www.businesswire.com/news/home/20260727193803/en/Enhanced-Applauds-FDA-Advisory-Committees-Landmark-Vote-to-Expand-Legal-Compounding-Pathway-for-Peptides

Filed to the library as 010, and with that filing Sunday's Monday-production run now stands down for this slot — the weekly series itself is untouched.

A Spoke-Media production:

https://www.spoke-media.com


adbl_web_anon_alc_button_suppression_t1
No reviews yet